Lupin receives tentative USFDA approval for Apixaban oral suspension

Hyderabad, Sept 28 (UNI) Global pharmaceutical major Lupin Limited on Monday announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its New Drug Application for Apixaban Oral Suspension 1.25 mg/mL through the 505(b)(2) regulatory pathway. The oral liquid formulation contains apixaban, the active ingredient in Bristol Myers Squibb's Eliquis, and offers an alternative administration option for adult patients requiring anticoagulation therapy, including those who have difficulty swallowing tablets, the Mumbai based pharma company said in a release. "This tentative approval reflects our continued focus on developing differentiated medicines that address meaningful patient…